SCHEMBL24635162

SCHEMBL24635162

CNc1ccc2ccc(C[PH](c3ccccc3)(c3ccccc3)c3ccccc3)cc2n1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 2/20 0.49
MAOB P27338 3/20 0.38
NUDT1 P36639 1/20 0.36
METTL3 Q86U44 5/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
NOS1 P29475 2/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
NOS2 P35228 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
NOS3 P29474 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8393731 0.74 NCF1 (0.52) NCF1MAOBMETTL3SMN1; SMN2NPC1
SCHEMBL20475558 0.73 NCF1 (0.50) NCF1MAOBMETTL3NOS1NOS2
SCHEMBL23283355 0.73 NCF1 (0.50) NCF1MAOBMETTL3NOS1NOS2
SCHEMBL23273967 0.73 NCF1 (0.50) NCF1MAOBMETTL3NOS1NOS2
SCHEMBL29970938 0.73 NCF1 (0.50) NCF1MAOBMETTL3NOS1NOS2
SCHEMBL5972991 0.72 CYP1A2 (0.50) KMT2A
SCHEMBL14103941 0.71 NCF1 (0.48) NCF1METTL3NOS1NOS2
SCHEMBL24875987 0.71 KDM4E (0.39) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL22521545 0.70 NCF1 (0.47) NCF1MAOBMETTL3NOS1NOS2
SCHEMBL8039395 0.70 NCF1 (0.47) NCF1METTL3SMN1; SMN2NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220372040-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220372040-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 NCF1 2895/4885MAOB 2305/4885NUDT1 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.